Breaking News Instant updates and real-time market news.

IBM

IBM

$159.50

-2.72 (-1.68%)

, PFE

Pfizer

$31.74

-0.4 (-1.24%)

12:52
12/01/16
12/01
12:52
12/01/16
12:52

IBM, Pfizer announce collaboration on immuno-oncology research

IBM (IBM) Watson Health and Pfizer (PFE) announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight cancer. Mikael Dolsten, President, Pfizer Worldwide Research & Development, said, "With the incredible volume of data and literature available in this complex field, we believe that tapping into advanced technologies can help our scientific experts more rapidly identify novel combinations of immune-modulating agents. We are hopeful that by leveraging Watson's cognitive capabilities in our drug discovery efforts, we will be able to bring promising new immuno-oncology therapeutics to patients more quickly."

IBM

IBM

$159.50

-2.72 (-1.68%)

PFE

Pfizer

$31.74

-0.4 (-1.24%)

  • 01

    Dec

  • 04

    Dec

IBM IBM
$159.50

-2.72 (-1.68%)

11/10/16
BOFA
11/10/16
UPGRADE
BOFA
Buy
IBM upgraded to Buy from Neutral at BofA/Merrill
11/10/16
11/10/16
UPGRADE
Target $185

Buy
IBM upgraded to Buy on earnings growth at BofA/Merrill
As previously reported, BofA/Merrill upgraded IBM to Buy from Neutral and raised its price target to $185 from $170. Analyst Wamsi Mohan expects 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. Further, the analyst expects IBM transnational revenues to recovery driven by the mainframe cycle in 2017 and the adoption of a Hybrid cloud model. Mohan said IBM is the most under owned tech named by large-cap US fund managers and provides upside from accumulation.
11/10/16
11/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Buy from Hold at Stifel while the firm upgraded Expedia (EXPE) to Hold from Sell. 2. IBM (IBM) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan expecting 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. 3. L-3 Communications (LLL) and Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Barclays while the firm upgraded Lockheed Martin (LMT) to Equal Weight from Underweight. 4. Microsoft (MSFT) upgraded to Neutral from Underweight at Atlantic Equities. 5. Novartis (NVS) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/01/16
JEFF
12/01/16
NO CHANGE
Target $125
JEFF
Underperform
IBM likely decline in earnings not reflected in stock, says Jefferies
Jefferies analyst James Kisner said his analysis suggests that IBM's software service/support revenue may have declined 4% in calendar 2015 and could also be falling organically this year, which he calls "particularly troubling" in light of steep declines in transactional sales. Continuing annual declines of roughly 3% in the Software business could drive a 5-6% headwind to EPS annually through 2020, Kisner tells investor. The analyst cut his EPS estimates for IBM based on reduced expectations for the Software business and expectations for 2017 IP Income to be below consensus. Kisner reiterates his Underperform rating and $125 price target on IBM shares.
PFE Pfizer
$31.74

-0.4 (-1.24%)

11/02/16
ARGS
11/02/16
DOWNGRADE
ARGS
Hold
Pfizer downgradedon weaker outlook at Argus
As noted earlier, Argus downgraded Pfizer to Hold from Buy. Analyst Jacob Kilstein cited "recent pipeline setbacks, prospects for increased competition, and management's decision to shelve its business separation plan" as reasons for the downgrade.
11/02/16
11/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Hold from Buy at Argus and to Market Perform from Outperform at BMO Capital. 2. BP (BP) downgraded to Hold from Buy at Societe Generale. 3. Corning (GLW) downgraded to Buy from Conviction Buy at Goldman with analyst Doug Clark saying the restocking phase of glass/TV cyclical recovery is now "well understood and largely behind us." 4. Adeptus Health (ADPT) downgraded to Underperform from Buy at BofA/Merrill, to Hold from Buy at Jefferies, and to Equal Weight from Overweight at Stephens. 5. Brookdale Senior Living (BKD) downgraded to Underperform from Neutral at BofA/Merrill, to Market Perform from Outperform at Wells Fargo, and to Outperform from Top Pick at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/16
LEHM
11/29/16
UPGRADE
Target $38
LEHM
Overweight
Pfizer upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Pfizer to Overweight and raised its price target to $38 from $37. Meacham sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders.
11/29/16
11/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying he sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders. 2. Comerica (CMA) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Tractor Supply (TSCO) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying he expects the company to benefit from colder weather and the improving US economy and said product assortments and promotions have also been adjusted to the new economics of the energy patch and its impact on this company's customers. 4. Del Frisco's (DFRG) upgraded to Outperform from Neutral at Credit Suisse with analyst Jason West saying it is a key beneficiary of improved high-end consumer and corporate spending. 5. Veracyte upgraded to Buy from Neutral at Janney Capital with analyst Paul Knight saying the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

19:34
04/23/17
04/23
19:34
04/23/17
19:34
Periodicals
Two California retirement systems vote against Wells directors, Reuters says »

Two of California's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

AAL

American Airlines

$45.15

-0.07 (-0.15%)

, UAL

United Continental

$69.56

-0.24 (-0.34%)

19:22
04/23/17
04/23
19:22
04/23/17
19:22
Periodicals
American Airlines suspends flight attendant after Friday altercation, WSJ says »

Video of an American…

AAL

American Airlines

$45.15

-0.07 (-0.15%)

UAL

United Continental

$69.56

-0.24 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FB

Facebook

$143.68

-0.12 (-0.08%)

19:11
04/23/17
04/23
19:11
04/23/17
19:11
Periodicals
Facebook seeks deals with publishers for video production, Recode says »

As part of a bid to push…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

HLX

Helix Energy

$7.09

-0.19 (-2.61%)

18:25
04/23/17
04/23
18:25
04/23/17
18:25
Earnings
Helix Energy reports Q1 EPS (11c), consensus (13c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

CMCSA

Comcast

$38.16

0.16 (0.42%)

, CMCSK

Comcast

18:17
04/23/17
04/23
18:17
04/23/17
18:17
Hot Stocks
Box Office Battle: 'Fate Of The Furious' nears global $1B in second weekend »

Comcast's (CMCSA)…

CMCSA

Comcast

$38.16

0.16 (0.42%)

CMCSK

Comcast

FOX

21st Century Fox

$30.22

-0.33 (-1.08%)

FOXA

21st Century Fox

$30.70

-0.37 (-1.19%)

DIS

Disney

$114.44

-0.35 (-0.30%)

TWX

Time Warner

$99.84

-0.16 (-0.16%)

LGF.A

Lionsgate

$26.08

0.11 (0.42%)

LGF.B

Lionsgate

$23.90

0.01 (0.04%)

SNE

Sony

$33.68

0.85 (2.59%)

VIA

Viacom

$45.05

-1 (-2.17%)

VIAB

Viacom

$43.10

-1.23 (-2.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 10

    May

  • 24

    May

  • 25

    May

  • 15

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:46
04/23/17
04/23
17:46
04/23/17
17:46
Earnings
C.R. Bard raises FY17 adjusted EPS to $11.65-$11.90 from $11.45-$11.75 »

EPS consensus $11.64.…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:43
04/23/17
04/23
17:43
04/23/17
17:43
Earnings
C.R. Bard sees Q2 adjusted EPS $2.75-$2.85, consensus $2.87 »

Sees Q2 revenue growth…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:41
04/23/17
04/23
17:41
04/23/17
17:41
Earnings
C.R. Bard reports Q1 adjusted EPS $2.87, consensus $2.65 »

Reports Q1 revenue…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:38
04/23/17
04/23
17:38
04/23/17
17:38
Hot Stocks
Becton Dickinson names Polen as president, says will lead Bard segment »

BD (BDX) announced the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

HCMLY

LafargeHolcim

$11.56

-0.1 (-0.86%)

17:32
04/23/17
04/23
17:32
04/23/17
17:32
Periodicals
LafargeHolcim CEO set to step down, FT reports »

LafargeHolcim CEO Eric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:30
04/23/17
04/23
17:30
04/23/17
17:30
Hot Stocks
Becton Dickinson outlines strategic highlights of C.R. Bard acquisition »

Expanding on the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

KLRE

KLR Energy Acquisition

$10.40

-0.02 (-0.19%)

17:29
04/23/17
04/23
17:29
04/23/17
17:29
Conference/Events
KLR Energy Acquisition to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:23
04/23/17
04/23
17:23
04/23/17
17:23
Hot Stocks
BD sees forming third business segment, says Bard CEO to join board »

Commenting on its…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:20
04/23/17
04/23
17:20
04/23/17
17:20
Hot Stocks
BD sees high single-digit EPS accretion in FY19 »

"This financially…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:18
04/23/17
04/23
17:18
04/23/17
17:18
Hot Stocks
Becton Dickinson says expects to continue buyback suspension »

"BD expects to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:16
04/23/17
04/23
17:16
04/23/17
17:16
Hot Stocks
Becton Dickinson to acquire C.R. Bard in $24B cash and stock deal »

BD (BDX) and C. R. Bard…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:10
04/23/17
04/23
17:10
04/23/17
17:10
Hot Stocks
Breaking Hot Stocks news story on Becton Dickinson, C.R. Bard »

Becton Dickinson to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

CS

Credit Suisse

$14.45

-0.09 (-0.62%)

17:07
04/23/17
04/23
17:07
04/23/17
17:07
Periodicals
Credit Suisse to determine capital raise plan after annual meeting, Reuters says »

Credit Suisse will make a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$142.27

-0.17 (-0.12%)

17:04
04/23/17
04/23
17:04
04/23/17
17:04
Periodicals
Uber CEO ordered iPhone tracking, was scolded by Tim Cook, NYT says »

Beginning in 2014, ride…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

AVID

Avid Technology

$5.11

0.19 (3.86%)

, MSFT

Microsoft

$66.40

0.9 (1.37%)

16:30
04/23/17
04/23
16:30
04/23/17
16:30
Hot Stocks
Avid announces strategic cloud alliance with Microsoft »

Avid (AVID) announced it…

AVID

Avid Technology

$5.11

0.19 (3.86%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 09

    May

  • 09

    May

15:44
04/23/17
04/23
15:44
04/23/17
15:44
Conference/Events
Wolfe Research utilities analyst holds an analyst/industry conference call »

Utilities Analyst…

OA

Orbital ATK

$97.28

-0.65 (-0.66%)

15:32
04/23/17
04/23
15:32
04/23/17
15:32
Hot Stocks
Breaking Hot Stocks news story on Orbital ATK »

Orbital ATK says Cygnus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$1.41

-0.09 (-6.00%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Hot Stocks
ContraVir presents data on hepatitis B candidates TXL, CRV431 »

ContraVir Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASPS

Altisource

$24.05

-1.39 (-5.46%)

, NRZ

New Residential

$16.34

-0.05 (-0.31%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Conference/Events
Piper Jaffray specialty finance analyst holds analyst/industry conference call »

Regional Banks &…

ASPS

Altisource

$24.05

-1.39 (-5.46%)

NRZ

New Residential

$16.34

-0.05 (-0.31%)

OCN

Ocwen

$2.42

-0.07 (-2.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    May

  • 24

    May

MRK

Merck

$61.89

-0.66 (-1.06%)

15:27
04/23/17
04/23
15:27
04/23/17
15:27
Hot Stocks
Merck reports new Phase 2 MK-3682B data »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 09

    Jun

  • 14

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.